Compared to a treatment regimen containing PARP inhibitor, significantly higher ORs of anemia (OR, 2.06, 95% CI 1.08, 3.93), leukopenia (OR 1.74, 95% CI 1.05, 2.89), diarrhea (OR 1.84, 95% CI 1.12, 3.04), and alopecia (OR 6.06, 95% CI 2.95, 12.44) were observed for the treatment regimens including both PARP inhibitors and platinum. Here, PARP1 is linked to anemia (phenotype).